Centre for Endocrinology and Reproductive Medicine, Italy
Quick facts
Marketed products
Phase 3 pipeline
- GM-CSF group · Oncology
GM-CSF (granulocyte-macrophage colony-stimulating factor) stimulates the production and activation of granulocytes and macrophages to enhance immune response.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Centre for Endocrinology and Reproductive Medicine, Italy portfolio CI brief
- Centre for Endocrinology and Reproductive Medicine, Italy pipeline updates RSS
Frequently asked questions about Centre for Endocrinology and Reproductive Medicine, Italy
What are Centre for Endocrinology and Reproductive Medicine, Italy's marketed drugs?
Top marketed products include Aromatase inhibitor and GnRH analog, GM-CSF medium, GnRH analog alone.
What is Centre for Endocrinology and Reproductive Medicine, Italy's pipeline?
Centre for Endocrinology and Reproductive Medicine, Italy has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include GM-CSF group.